New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:02 EDTCLVSClovis receives breakthrough therapy designation for CO-1686
Clovis Oncology announced that the FDA has granted Breakthrough Therapy designation for the company’s investigational agent CO-1686 as monotherapy for the treatment of second-line EGFR mutant NSCLC in patients with the T790M mutation. The Breakthrough Therapy designation was granted based on interim efficacy and safety results from an ongoing Phase 1/2 study of CO-1686. CO-1686 is the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor, or EGFR, for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
07:27 EDTCLVSClovis price target raised to $125 from $90 at Stifel
Subscribe for More Information
May 15, 2015
10:01 EDTCLVSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:04 EDTCLVSClovis downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
May 14, 2015
16:19 EDTCLVSOn The Fly: Top stock stories for Thursday
Subscribe for More Information
09:22 EDTCLVSLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
05:52 EDTCLVSMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
17:23 EDTCLVSClovis announces ASCO presentations including TIGER-X study update
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use